title: Anti-CD30 Antibodies for Hodgkin lymphoma.
abstract: Treatment of refractory or relapsed classical Hodgkin lymphoma (HL) remains challenging, but targeted immunotherapy has recently emerged as a potential treatment option for these patients. Although first-generation monoclonal anti-CD30 antibodies proved disappointing, current efforts to modify anti-CD30 antibodies to improve binding of effector cells and enhance activity appears more promising, as does the development of novel antibody-drug conjugates (ADCs). ADCs offer the potential to deliver potent therapies with minimal toxicity. One highly active ADC, brentuximab vedotin (SGN-35), combines an anti-CD30 monoclonal antibody and the antitubulin agent monomethyl auristatin E. Initial phase 1 studies of brentuximab vedotin showed a 52% overall response rate in relapsed HL, with minimal toxicity. This article highlights the development of anti-CD30 antibodies and ADCs for relapsed or refractory classical HL.
authors.affiliation: Washington University School of Medicine, Siteman Cancer Center, 660 South Euclid, Box 8056, St. Louis, MO 63110, USA.
authors.forename: Kelley V
authors.initials: KV
authors.lastname: Foyil
authors.forename: Nancy L
authors.initials: NL
authors.lastname: Bartlett
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000079963:Brentuximab Vedotin; D002986:Clinical Trials as Topic; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use; D007167:Immunotherapy; D017730:Ki-1 Antigen / Q000276:immunology*; D009842:Oligopeptides / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D018796:Immunoconjugates; D017730:Ki-1 Antigen; D009842:Oligopeptides; D000079963:Brentuximab Vedotin; C495575:monomethyl auristatin E
references.citation: Proc Natl Acad Sci U S A. 2007 May 15;104(20):8444-8
references.pmid: 17488826
references.citation: J Clin Invest. 1997 Sep 1;100(5):1059-70
references.pmid: 9276722
references.citation: J Clin Oncol. 2007 Jul 1;25(19):2764-9
references.pmid: 17515574
references.citation: Leukemia. 2005 Sep;19(9):1648-55
references.pmid: 16049514
references.citation: Int J Cancer. 1995 Feb 8;60(4):539-44
references.pmid: 7530238
references.citation: Br J Haematol. 2008 Jul;142(1):69-73
references.pmid: 18477046
references.citation: Blood. 2003 Nov 15;102(10):3737-42
references.pmid: 12881320
references.citation: Blood. 2009 Jun 4;113(23):5920-6
references.pmid: 19188663
references.citation: Hematology Am Soc Hematol Educ Program. 2009;:507-19
references.pmid: 20008236
references.citation: Cancer. 2003 Jul 15;98(2):310-4
references.pmid: 12872350
references.citation: Cancer. 2002 Jan 1;94(1):1-5
references.pmid: 11815953
references.citation: Cancer Res. 2002 Jul 1;62(13):3736-42
references.pmid: 12097283
references.citation: Blood. 2008 Feb 15;111(4):1848-54
references.pmid: 18079362
references.citation: Lancet. 1992 May 16;339(8803):1195-6
references.pmid: 1349939
references.citation: Nat Biotechnol. 2003 Jul;21(7):778-84
references.pmid: 12778055
references.citation: N Engl J Med. 2010 Mar 11;362(10):875-85
references.pmid: 20220182
references.citation: Blood. 2009 Mar 19;113(12):2765-3775
references.pmid: 19096012
references.citation: Blood. 1998 Jan 15;91(2):399-405
references.pmid: 9427692
references.citation: Bioconjug Chem. 2002 Jul-Aug;13(4):855-69
references.pmid: 12121142
references.citation: Cancer Res. 2001 Dec 15;61(24):8737-42
references.pmid: 11751393
references.citation: Clin Cancer Res. 2002 Jun;8(6):1779-86
references.pmid: 12060617
references.citation: J Immunol Methods. 2005 Nov 30;306(1-2):151-60
references.pmid: 16219319
references.citation: Blood. 1997 Aug 1;90(3):1109-14
references.pmid: 9242542
references.citation: Br J Haematol. 2009 Jul;146(2):171-9
references.pmid: 19466965
references.citation: Cancer Res. 2005 Sep 15;65(18):8331-8
references.pmid: 16166310
references.citation: Blood. 2008 Apr 1;111(7):3830-7
references.pmid: 18230757
references.citation: Clin Cancer Res. 2004 Oct 15;10(20):7063-70
references.pmid: 15501986
references.citation: Lab Invest. 2000 Jul;80(7):1111-9
references.pmid: 10908157
references.citation: Ann Oncol. 2007 Jun;18(6):1071-9
references.pmid: 17426059
references.citation: Clin Cancer Res. 2009 May 15;15(10):3376-83
references.pmid: 19401346
references.citation: J Clin Oncol. 2005 Jul 20;23(21):4669-78
references.pmid: 16034043
references.citation: Protein Eng Des Sel. 2006 Jul;19(7):299-307
references.pmid: 16644914
references.citation: Bioconjug Chem. 2005 Sep-Oct;16(5):1282-90
references.pmid: 16173809